Realty Income's YTD pullback improves yield but unresolved dilution and earnings quality keep us cautious

What happened

Realty Income stock has fallen to year-to-date lows in September 2026, with the forward dividend yield reaching ~5.8% and the stock trading at ~12.7x forward AFFO, according to a recent Seeking Alpha article. This decline comes after a period of relative stability in mid-2026, when the stock traded around $61.7 and our DeepValue master report rated it WAIT with an attractive entry of $58. The article highlights management's raised 2026 AFFO and investment volume guidance, as well as expanded private capital partnerships aimed at reducing reliance on equity issuance. However, the master report's concerns remain: as of May 2026, O had 23.6M shares under ATM forward sales, elevated impairments ($129M in Q1 2026), and unusually high lease termination income ($40M in Q1 2026). The stock's decline may have priced in some of these risks, but the fundamental picture is mixed, with the possibility of further dilution if equity settlement persists.

Implication

The stock's decline below our prior entry level improves the risk/reward, but the unresolved ATM forward overhang and earnings quality issues argue for patience. Investors should monitor the Q2 2026 earnings call for updates on ATM settlement activity and any revision to the 23.6M share forward position. A meaningful reduction in forward shares or a shift toward private capital funding would be a positive signal. Conversely, if impairments and termination income remain elevated, the 'stable cash flow' narrative weakens further. We suggest a scaled approach: consider initial positions on further weakness toward the bear-case $54, but avoid overcommitting until there is hard evidence of per-share AFFO accretion without excessive dilution.

Thesis delta

The pullback since June has brought the stock below our prior $58 entry level, improving the forward yield to ~5.8% and the valuation to ~12.7x AFFO. However, the core concerns—23.6M unsettled ATM forward shares, elevated impairments, and reliance on one-off termination income—remain unresolved as of the latest filings. We therefore shift from a wait-for-better-entry stance to a closer monitoring posture, but do not yet upgrade to a full buy until Q2/Q3 data confirm dilution control and earnings quality normalization.